One page, thousands of outlets. See who else covered it.
Broadcom's sales are expected to grow dramatically in 2027.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
Record bookings and backlog fuel margin expansion as military programs accelerate.
Lorundrostat advances toward December FDA decision as company ramps commercial launch.
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.
Revenue grew to $2 million as spectrum monetization opportunities expand.
Antimony prices collapsed, but zeolite surged 110% and government contracts accelerate.
VigilAigent acquisition adds $3.5M ARR as company targets 2027 profitability.